The 2024 ADA guidelines recommend GLP-1 RAs and SGLT-2is, with or without metformin depending on glycemic control needs, as initial therapeutic agents for patients with T2DM and comorbid ASCVD, heart failure, or chronic kidney disease (American Diabetes Association, 2024). Here, GLP1R is linked to heart failure.